Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of LY3471851 (NKTR-358) in Adults With Systemic Lupus Erythematosus

NCT04433585 is registered in ClinicalTrials.gov with Nektar Therapeutics as lead sponsor.

NCT NCT04433585
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04433585 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of LY3471851 (NKTR-358) in Adults With Systemic Lupus Erythematosus
Lead sponsor
Nektar Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
August 19, 2020
Completion date
February 16, 2023
Enrollment
291 (actual)
Sites
112

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus